The drug grabbed a 10.7% share of the US PPI market and is now the third most heavily prescribed drug of its kind, the company reported. It sold 80 million dollars in the first 6 months of the year.
The drug has achieved a comparable market share in Germany, Norway and Finland and has been launched in 20 markets.
The company reported a slight decline in sales of Prilosec (omeprazole), but this was outweighed by its sales of Nexium.
But sales of Losec (omeprazole) continued to increase in Europe - by 4% - especially in the UK, France and Italy.
|Nexium grabbed a 10.7% share of the US PPI market|
AstraZeneca Chief Executive Tom McKillop said, "The successful launches of Nexium and Symbicort (eformoterol and budesonide), and the good progress with our strong pipeline, mark a promising start to the transformation of our portfolio and provide the platform for future growth."
Meanwhile, HCV drug developers a href="http://www.schering-plough.com/" target="_blank">Schering-Plough bounced back from a disappointing quarterly report. They were boosted by US Food and Drug Administration approval for the marketing of Rebetol (ribavirin) as a separate product.
The company had seen a decline of 13% of sales of its Intron A (interferon) HCV therapies in the US market, apparently while physicians waited for FDA rulings.
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com